TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究*

doi:10.3969/j.issn.1672-5069.2023.01.030

摘要/Abstract

摘要： 目的观察采用肝动脉化疗栓塞(TACE)术联合卡瑞利珠单抗治疗中晚期原发性肝癌(PLC)患者的临床效果。方法 2018年3月～2021年3月安徽省宿州市第一人民医院收治的中晚期PLC患者116例,采用随机数字表法将其分对照组58例和观察组58例,分别给予TACE治疗或在TACE治疗的基础上给予卡瑞利珠单抗治疗。采用ELISA法检测血清癌胚抗原(CEA)、甲胎蛋白(AFP)和甲胎蛋白异质体(AFP-L3)水平,使用流式细胞仪检测外周血T淋巴细胞亚群。采用Kaplan-Meier法绘制生存曲线,采用Log-Rank检验。结果治疗后,观察组获得完全缓解率、部分缓解率、疾病稳定率、客观缓解率和疾病控制率分别为8.6%、48.3%、29.3%、56.9%和86.2%,而对照组则分别为1.7%、36.2%、31.0%、37.9%(P<0.05)和69.0%(P<0.05);观察组血清甲胎蛋白、甲胎蛋白异质体和癌胚抗原水平分别为(86.5±28.7)ng/mL、(183.7±61.4)ng/mL和(9.1±2.6)ng/mL,显著低于对照组[分别为(185.8±34.9)ng/mL、270.3±71.5)ng/mL和(25.4±3.6)ng/mL,P＜0.05];观察组外周血CD4^＋细胞百分比和CD4^＋/CD8^＋比值分别为(38.6±4.1)%和(1.3±0.2),显著高于对照组【分别为(32.3±3.7)%和(1.1±0.1),P＜0.05】;截止到随访结束,观察组和对照组生存率分别为64.3%(36/56)和43.9%(25/57,x²=3.618,P=0.045)。结论采取TACE联合卡瑞利珠单抗治疗中晚期PLC患者有一定的近期疗效,还需要扩大观察。

关键词: 原发性肝癌, 中晚期, 肝动脉化疗栓塞, 卡瑞利珠单, 临床疗效, 预后生存

Abstract: Objective The aim of this study was to observe the clinical efficacy of camrelizumab therapy after transhepatic arterial chemoembolization (TACE) in the treatment of patients with advanced primary liver cancer (PLC). Methods A total of 116 patients with advanced PLC were admitted to Suzhou First People's Hospital between March 2018 and March 2021, and randomly divided into control and observation group, with 58 patients in each group. The patients in the control group were treated with TACE, and those in the observation group were treated with TACE and after that the carrierizumab was given for six months to one year. Serum alpha fetoprotein (AFP), alpha fetoprotein heterogeneity-L3 (AFP - L3) and carcinoembryonic antigen (CEA) levels were detected by ELISA. The peripheral blood T lymphocyte subsets were determined by FCM. The survival curve was drawn by Kaplan-Meier and compared by Log-Rank test. Results At the end of three month treatment, the complete remission, partial remission, stable disease, objective remission rate and disease control rate in the observation group were 8.6%, 48.3%, 29.3%, 56.9% and 86.2%, much superior to 1.7%, 36.2%, 31.0%, 37.9%(P<0.05) and 69.0%(P<0.05) in the control group; serum AFP, AFP - L3 and CEA were(86.5±28.7)ng/mL, (183.7±61.4)ng/mL and (9.1±2.6)ng/mL, significantly lower than [(185.8±34.9)ng/mL, 270.3±71.5)ng/mL and (25.4±3.6)ng/mL, respectively, P＜0.05] in the control; the percentage of peripheral blood CD4^＋ cells and the CD4^＋/CD8^＋ cell ratio were (38.6±4.1)% and (1.3±0.2), both significantly higher than [(32.3±3.7)% and (1.1±0.1), respectively, P＜0.05] in the control; up to the end of two-year follow-up, the survival rate in the observation group with two missed was 64.3%(36/56), much higher than 43.9%(25/57, x²=3.618, P=0.045) in the control with one missed. Conclusion We recommend the carlizumab therapy after TACE in the treatment of patients with advanced PLC, which needs further clinical investigation.

Key words: Hepatoma, Transhepatic arterial chemoembolization, Carrelizumab, Therapy, Prognosis

杜尚云, 翁莉, 武敏. TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 116-119.

Du Shangyun, Weng Li, Wu Min. Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer[J]. Journal of Practical Hepatology, 2023, 26(1): 116-119.

参考文献

[1] Luo Y, Jiang Y. Comparison of efficiency of TACE plus hifu and TACE alone on patients with primary liver cancer. J Coll Physicians Surg Pak, 2019, 29(5):414-417.
[2] 徐宏伟, 孙德生, 徐惠亮, 等. 碳酸氢钠肝动脉灌注联合TACE治疗中晚期原发性肝癌的疗效观察.介入放射学杂志, 2021, 30(9):932-936.
[3] Sun Y, Ji S, Ji H, et al. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined withradiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON, 2019, 24(4):1402-1407.
[4] Kim D, Lee J H, Moon H, et al. Development and evaluation of an ultrasound-triggered microbubble combined transarterial chemoembolization (TACE) formulation on rabbit VX2 liver cancer model. Theranostics, 2021, 11(1):79-92.
[5] 刘秀芳, 张伟伟. 多学科协作干预模式在TACE治疗原发性肝癌患者中的应用效果.介入放射学杂志, 2021, 30(10):1057-1060.
[6] Peng Z, Wei J, Wang F, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res, 2021, 27(11):3069-3078.
[7] 中国抗癌协会肝癌专业委员会. 原发性肝癌规范化病理诊断指南(2015年版). 中华肝胆外科杂志, 2015, 31(6):833-839.
[8] Han K, Kim J H. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system. World J Gastroenterol, 2015, 21(36):10327-10335.
[9] Marina O, Suh J H, Reddy C A, et al. Treatment outcomes for patients with glioblastoma multiforme and a low Karnofsky Performance Scale score on presentation to a tertiary care institution. J Neurosurg, 2011, 115(2):220-229.
[10] Eisenhauer E A, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009, 45(2):2411-247.
[11] Boyd M R, Paull K D. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Devel Res, 2010, 34(2):91-109.
[12] Jin J, Zhou T, Lou J,et al. Efficacy of licartin combined with transcatheter hepatic arterial chemoembolization in the treatment of middle-advanced primary liver cancer. J BUON, 2020, 25(6):2584-2591.
[13] Xie L, Qian Z, Xu J. Clinical intervention effect of TACE combined with3DCRT in patients with primary liver cancer. Am J Transl Res, 2021, 13(7):7960-7967.
[14] Taylor A C, Maddirela D, White S B. Role of radioembolization for biliary tract and primary liver cancer. Surg Oncol Clin N Am, 2019, 28(4):731-743.
[15] Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut, 2020, 69(8):1492-1501.
[16] 李梅, 宋娟荣, 翟鹏涛, 等. 载药微球在原发性肝癌TACE治疗中疗效及安全性分析.介入放射学杂志, 2021, 30(2):186-190.
[17] Song H, Liu X, Jiang L, et al. Current status and prospects of camrelizumab, a humanized antibody against programmed cell death receptor 1. Recent Pat Anticancer Drug Discov, 2021,16(3):312-332.
[18] 顾杰, 许晨, 周卫忠, 等. TACE联合阿帕替尼对比单独TACE治疗中晚期原发性肝癌的倾向性匹配分析. 介入放射学杂志, 2021, 30(7):724-729.
[19] 杨秋雨, 魏宁, 徐浩, 等. TACE联合卡瑞利珠单抗治疗中晚期肝癌短期疗效及疗效相关性分析. 医学影像学杂志, 2021, 31(7):1212-1219.
[20] Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the escort-1st randomized clinical trial. JAMA, 2021, 326(10):916-925.
[21] Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med, 2021, 9(3):305-314.
[22] Reguart N, Reyes R. Spotlight on camrelizumab in advanced squamous lung cancer: another feather in the cap of Chinese checkpoint inhibitors. J Thorac Oncol, 2022, 17(4):477-480.

TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究^*

Clinical observation of camrelizumab therapy after TACE in the treatment of patients with advanced primary liver cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁海斌, 张欣, 李雅, 聂磊, 常柏玲, 王颖栋. TACE序贯微波消融联合索拉非尼治疗大肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2023, 26(1): 108-111.
[2]	彭雨, 李海涛, 杨文丽, 余意. PD-1抑制剂联合仑伐替尼治疗老年中晚期原发性肝癌患者临床疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 112-115.
[3]	张子侠, 李德林, 张国梁. RFA联合益脾养肝方治疗原发性肝癌患者临床疗效观察[J]. 实用肝脏病杂志, 2023, 26(1): 142-144.
[4]	毛月琴, 张红侠, 宋海燕, 刘波, 董静, 陈照林, 杨小康, 周旭, 娄方明. TACE联合毒痰瘀脾虚方治疗原发性肝癌患者临床疗效研究[J]. 实用肝脏病杂志, 2022, 25(6): 873-876.
[5]	邬政宏, 吴冬秋, 刘四斌. DCE-MRI诊断原发性肝癌效能和TACE术后评估肿瘤活性应用价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 881-884.
[6]	蓝思荣, 徐继威, 张耀明, 李雄, 沈登文, 苏鸿辉. 实时超声造影与3D超声融合成像导航评估微波消融治疗原发性肝癌患者价值研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 889-892.
[7]	李季, 周仲松, 郜玉峰, 薛继华, 张骏飞. 超声融合导航技术指导微波消融治疗小肝癌临床价值研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 698-701.
[8]	樊顺克, 王贵罗, 伊晓燕. 七氟醚联合丙泊酚静-吸复合麻醉用于原发性肝癌根治术治疗经验介绍^*[J]. 实用肝脏病杂志, 2022, 25(5): 702-705.
[9]	张凯, 刘培培, 饶石磊, 王琦, 岳恺, 王旸, 杨峥, 张松. 三维适形放射治疗不同大体肿瘤体积的原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 710-713.
[10]	李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.
[11]	周宇, 耿进朝, 韩雪, 于建华, 回瑾, 李岩, 李微. 射频消融治疗原发性肝癌患者疗效评价^*[J]. 实用肝脏病杂志, 2022, 25(5): 718-721.
[12]	王宝锋, 马彦高, 李义, 曾宪强, 周进学. 增强MRI扫描在乙型肝炎肝硬化背景下对原发性肝癌的诊断价值分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 554-557.
[13]	刘浩, 周菲菲, 孙好凯, 刘永刚. 基于CBCT的三维重建技术用于TACE术治疗原发性肝癌患者对肿瘤供血动脉识别的价值^*[J]. 实用肝脏病杂志, 2022, 25(4): 563-566.
[14]	王远平, 郑露露, 张光亮. MRI与4DCT联合指导勾画原发性肝癌患者放疗靶区初步研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 567-570.
[15]	魏博文, 任峥, 张亮, 汪伟. 增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析[J]. 实用肝脏病杂志, 2022, 25(4): 603-604.